Skip to main content
Zhejiang Orient Gene Biotech Co., Ltd logo

Zhejiang Orient Gene Biotech Co., Ltd — Investor Relations & Filings

Ticker · 688298 ISIN · CNE100003RM8 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 693 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688298

About Zhejiang Orient Gene Biotech Co., Ltd

https://www.orientgene.com/

Zhejiang Orient Gene Biotech Co., Ltd. specializes in the research, development, manufacturing, and distribution of in vitro diagnostic (IVD) products. The company's portfolio encompasses a broad range of rapid testing kits, molecular diagnostics, and biochemical reagents. Key product categories include lateral flow assays for infectious diseases, drug of abuse testing, oncology markers, and cardiovascular health indicators. Orient Gene provides comprehensive diagnostic solutions through its integrated R&D and production facilities, serving a global market including healthcare providers and clinical laboratories. The company is recognized for its high-throughput manufacturing capabilities and adherence to international quality standards, facilitating the rapid deployment of diagnostic tools for public health challenges.

Recent filings

Filing Released Lang Actions
关于自愿披露获得医疗器械注册证的公告
Regulatory Filings Classification · 82% confidence The document is an official stock exchange announcement by Zhejiang Orient Gene Biotech (证券代码：688298) regarding the voluntary disclosure of newly obtained and renewed medical device registration certificates. It provides detailed tables of product names, certificate numbers, jurisdictions, and validity periods. There is no financial data, management change, merger activity, or investor presentation content. This type of compliance/regulatory update does not fit any specific category like earnings, dividends, or annual reports and therefore falls under the fallback “Regulatory Filings” category (RNS).
2026-05-26 Chinese
国浩律师（杭州）事务所关于浙江东方基因生物制品股份有限公司2025年年度股东会法律意见书
Regulatory Filings Classification · 89% confidence The document is a legal opinion letter (“法律意见书”) issued by Grandall Law Firm regarding the 2025 annual shareholders’ meeting of Zhejiang Dongfang Gene Bioproducts Co., Ltd. It is not the AGM minutes or presentation materials themselves, nor a standalone financial report or earnings release. Rather, it is a compliance/legal‐opinion document addressed to the company, certifying that the meeting’s convening, quorum, voting procedures, and results comply with Chinese Company Law and listing rules. This falls under general regulatory/compliance filings that do not require classification as a specific financial or corporate action report. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-20 Chinese
第四届董事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an official announcement of the resolutions passed at the first meeting of the newly elected fourth Board of Directors, detailing the election of a new Chairman and representative, plus the appointment of key senior management positions (General Manager, Board Secretary, Securities Affairs Representative, Deputy General Managers, and Financial Officer). This clearly falls under announcements of changes in the company’s board of directors and senior management. Therefore, it should be classified as Board/Management Information (MANG).
2026-05-20 Chinese
关于选举第四届董事会职工代表董事的公告
Board/Management Information Classification · 92% confidence The document is an official announcement by Zhejiang Dongfang Gene Biotech Co., Ltd. regarding the election of an employee representative director to its fourth board of directors. It details changes in the composition of the board, names the elected individual, and provides her qualifications. There are no financial statements or indications of a full report publication, nor is it a regulatory certification or proxy statement. This aligns with a Board/Management Information filing regarding changes in the company’s board of directors.
2026-05-20 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is titled “2025年年度股东会决议公告” and provides detailed shareholder meeting attendance and vote counts for multiple proposals, including voting percentages and quorum. It is clearly an announcement of voting results from the annual general meeting, matching the Definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-20 Chinese
关于完成董事会换届选举及聘任高级管理人员、证券事务代表的公告
Board/Management Information Classification · 95% confidence The document is a formal announcement by Zhejiang Oriental Gene Biotech Co., Ltd. regarding the completion of board election and the appointment of senior management and securities affairs representative. It details changes in the board of directors (new chairman, committee members) and the hiring of the general manager, board secretary, deputy general managers, and finance head. This fits the definition of Board/Management Information (MANG).
2026-05-20 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.